Viral efficacy maintained and safety parameters improved with a reduced dose of stavudine: a pilot study

Objectives Stavudine (d4T) is a potent but potentially toxic nucleoside reverse transcriptase inhibitor that is still widely used in developing countries. This study's aim was to determine the efficacy and safety profile of lower‐dose d4T. Methods Multi‐centre, open‐label, single‐arm, pilot, 48...

Full description

Saved in:
Bibliographic Details
Published in:HIV medicine 2008-10, Vol.9 (9), p.738-746
Main Authors: Ait‐Mohand, H, Bonmarchand, M, Guiguet, M, Slama, L, Marguet, F, Behin, A, Amellal, B, Bennai, Y, Peytavin, G, Calvez, V, Pialoux, G, Murphy, R, Katlama, C
Format: Article
Language:English
Subjects:
Adult
Aged
Antiretroviral Therapy, Highly Active - methods
CD4 Lymphocyte Count
combination antiretroviral therapy
Drug Administration Schedule
Female
HIV Infections - drug therapy
HIV Infections - virology
HIV-1
Human immunodeficiency virus
Humans
Male
Middle Aged
mitochondrial toxicity
nucleoside reverse transcriptase inhibitor
Pilot Projects
reduced‐dose stavudine
Reverse Transcriptase Inhibitors - administration & dosage
Reverse Transcriptase Inhibitors - pharmacokinetics
RNA, Viral - drug effects
Stavudine - administration & dosage
Stavudine - pharmacokinetics
Treatment Outcome
Viral Load
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives Stavudine (d4T) is a potent but potentially toxic nucleoside reverse transcriptase inhibitor that is still widely used in developing countries. This study's aim was to determine the efficacy and safety profile of lower‐dose d4T. Methods Multi‐centre, open‐label, single‐arm, pilot, 48‐week study in French patients weighing >60 kg with viral load
ISSN:1464-2662
1468-1293
DOI:10.1111/j.1468-1293.2008.00616.x